Vedolizumab for the Treatment of Collagenous Gastritis

Running, not enrolling · Phase 2

Conditions studied: Collagenous Gastritis

In brief

The goal of this clinical trial is to learn about how vedolizumab may affect patients with collagenous gastritis (CG). The main questions it aims to answer are: * Whether vedolizumab can reduce CG symptoms * Whether vedolizumab is safe to take for patients with CG Participants in this study will: * Receive vedolizumab through an IV ("infusion") * Complete a survey at each infusion visit * Have blood collected at each infusion visit * Undergo an endoscopy with biopsy at 2 timepoints

Key facts

Study ID

NCT06317220

Run by

Massachusetts General Hospital

People needed

11

Starts

2024-12-03

Expected to finish

2026-10-01

Last updated by the study team

2026-06-16

Who can join

Age: 14 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 14 or older
• Weight of at least 40kg
• Has a biopsy-confirmed diagnosis of collagenous gastritis
• Agrees to all required study procedures
• Presence of one or more collagenous gastritis symptom at a severity of Grade 1 or higher at the time of enrollment: abdominal pain, nausea, diarrhea, bloating, vomiting, flatulence, constipation, fatigue, headache, rash

You may not qualify if…

• Unable to independently provide informed consent or assent
• Allergic to vedolizumab or any of its components

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.